Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
| العنوان: | Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE |
|---|---|
| المؤلفون: | María José Méndez-Vidal, Enrique Gonzalez-Billalabeitia, Nuria Lainez, Urbano Anido, Álvaro Montesa, Miguel Angel Climent, J. P. Maroto, Javier Puente, Ángel Francisco Zazo Rodríguez, Curro Zambrana, Julio Lambea, A. González-del-Alba |
| المساهمون: | [Gonzalez-del-Alba, Aranzazu] Hosp Univ Puerta Hierro Majadahonda, Med Ongol Dept, Calle Joaquin Rodrigo 2, Madrid 28222, Spain, [Puente, Javier] Hosp Clin San Carlos, CIBERONC, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Med Oncol Dept, Madrid, Spain, [Anido, Urbano] Complejo Hosp Univ Santiago, Oncol Dept, Santiago De Compostela, Spain, [Angel Climent, Miguel] IVO, Med Oncol Dept, Valencia, Spain, [Gonzalez-Billalabeitia, Enrique] Univ Murcia, IMIB, Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, Murcia, Spain, [Gonzalez-Billalabeitia, Enrique] Univ Catolica San Antonio Murcia UCAM, Murcia, Spain, [Lainez, Nuria] Complejo Hosp Navarra, Med Oncol Dept, Pamplona, Spain, [Lambea, Julio] Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain, [Pablo Maroto, Jose] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain, [Jose Mendez-Vidal, Maria] Hosp Univ Reina Sofia, Med Oncol Dept, Cordoba, Spain, [Montesa, Alvaro] Hosp Reg Malaga, Med Oncol Dept, Malaga, Spain, [Rodriguez, Angel] Hosp Leon, Med Oncol Dept, Leon, Spain, [Zambrana, Curro] Hosp Univ Infanta Sofia, Med Oncol Dept, San Sebastian De Reyes, Spain, Sanofi |
| المصدر: | Therapeutic Advances in Medical Oncology, Vol 12 (2020) Zaguán: Repositorio Digital de la Universidad de Zaragoza Universidad de Zaragoza Zaguán. Repositorio Digital de la Universidad de Zaragoza instname Therapeutic Advances in Medical Oncology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| بيانات النشر: | SAGE Publishing, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Radium-223, medicine.medical_specialty, radium-223, medicine.medical_treatment, Docetaxel, Androgen deprivation therapy, Castration resistant, chemotherapy, lcsh:RC254-282, 1st-line, Upfront, Increased survival, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Internal medicine, medicine, Enzalutamide, 030212 general & internal medicine, Chemotherapy, Cabazitaxel, enzalutamide, business.industry, Abiraterone acetate, Men, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, metastatic castration-resistant prostate cancer, chemistry, 030220 oncology & carcinogenesis, androgen-deprivation therapy, business, medicine.drug |
| الوصف: | Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted ⩾7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations. Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1758-8359 1758-8340 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c0c26be19d7be0e8eed0ba68bd453c9Test https://doaj.org/article/75ff313d187749adb79d84a4a14b63f7Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7c0c26be19d7be0e8eed0ba68bd453c9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17588359 17588340 |
|---|